Lazarys turns today’s most powerful science into tomorrow’s cancer medicines.

learn more
Backed early by1517 Fund and Emergent Ventures
A figure on a swing made of immune cells, surrounded by pathogens
A patient in a hospital bed looking out at the sunrise

context

never not
sick.

What looks like a peaceful day is actually a very busy environment inside the body.

We exist in a highly controlled and delicate equilibrium, with the immune system constantly fighting hundreds of small battles to prevent pathogens and cancers from killing us.

Every now and then, this system falls into disorder. With cancer, we need to push the immune system back in the patient’s favor – back against the tumor, transiently, so that we can restore balance.

Push too far one way and you get unwanted toxicity. Too little and the immune system can’t find diseases or cancers.

Mother nature has already given us clues to a future where cancer no longer has to be a lethal disease. Research has now discovered thousands of proteins with anti-tumor effects.

We believe it’s time oncology got a major upgrade.

bottleneck

Today’s individual therapeutics, targets, and mechanisms leave escape routes.

Over 50 years of clinical research has shown that the right combinations produce deeper, longer-lasting responses.

Off-target effects limit which molecules and mechanisms we can combine and how much a patient can tolerate.

The most successful cancer drug
in the world still isn’t good enough:

in 2025, keytruda made $31b

Keytruda (pembrolizumab) bound to human PD-1
keytruda (pembrolizumab)bound to human pd-1
human pd-1
40+ indication approvals
redosed every 3-6 weeks
<50% of patients respond

what will bring the next great cancer medicines
from possibility into reality?

We’re building a platform to control where proteins are made, where they stay, and what they do.

and we’re starting with messenger RNA.

A Lazarys scientist pipetting samples at a biosafety cabinet

engine 1: genetic engineering

High-throughput screening for ever-improving control over which cells make therapeutic proteins.

engine 2: protein engineering

ML-enabled protein engineering adds tumor-binding functions to some proteins, helping retain therapeutic activity locally.

engine 3: pathway engineering

We combine therapeutic biology that attack cancer in powerful, clinically validated, complementary ways.

see our programs in motion

people

Leadership

A team of scientists, builders and operators committed to transforming cancer care through a new generation of what’s possible.

Dylan PaolettiFounder & CEO
Yildirim (“Yil”) Dogan, PhDCo-Founder & CSO
Peter Evans, PhD, MPHCo-Founder & Operations

Scientific Advisory Board

World-leading scientists and clinicians who advise our research, development and clinical strategy.

Chris Mason, MD, PhDProfessor of Cell and Gene Therapy, University College London; Founder & CEO, Sun Vectors
Axel Schambach, MD, PhDProfessor of Experimental Hematology, Hannover Medical School; President, ESGCT

our mission

Combination therapy made testicular, non-hodgkin lymphoma, and acute lymphoblastic leukemia curable.

Evolution has dictated that we exist in a delicate equilibrium with the laws and limits of our biology – inscribed in the letters of our genetic code; however, in our modern world, we sometimes have to bend those laws to correct things nature didn’t plan for if we want to survive.

Lazarys is turning today’s most powerful science into tomorrow’s cancer therapies – to redirect luck in the patient’s favor.

our vision

The future of oncology

  • looks like lazarys
  • redefines modalities
  • combines potent, validated biology
  • does more with less toxicity
  • looks like lazarys
  • redefines modalities
  • combines potent, validated biology
  • does more with less toxicity